Compounds > bimosiamose
Page last updated: 2024-11-11

bimosiamose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bimosiamose: a selectin inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9811353
CHEMBL ID1215923
SCHEMBL ID12182030
MeSH IDM0481217

Synonyms (33)

Synonym
CHEMBL1215923 ,
tbc 1269
(1,1'-biphenyl)-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis(6'-(alpha-d-mannopyranosyloxy)-
bimosiamose
(hexane-1,6-diylbis(6'-(alpha-d-mannopyranosyloxy)biphenyl-3',3-diyl))diacetic acid
tbc-1269
NCGC00183833-01
bimosiamose [inn]
1,6-bis(3-(3-carboxymethylphenyl)-4-(2-alpha-d-mannopyranosyloxy)phenyl)hexane
97b5kcw80w ,
187269-40-5
unii-97b5kcw80w
dtxsid8048783 ,
cas-187269-40-5
dtxcid4028709
tox21_113260
SCHEMBL12182030
1,6-bis[3-(3-carboxymethylphenyl)-4-(2-r-d-mannopyranosyloxy)phenyl]hexane
bdbm50324667
bimosiamose [mi]
(hexane-1,6-diylbis(6'-(.alpha.-d-mannopyranosyloxy)biphenyl-3',3-diyl))diacetic acid
bimo
2-[3-[5-[6-[3-[3-(carboxymethyl)phenyl]-4-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]hexyl]-2-[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]phenyl]acetic acid
compound 15e [pmid: 9544210]
gtpl9049
tbc1269
HY-106139
CS-0024963
DB06197
Q27075271
MS-31594
2,2'-(hexane-1,6-diylbis(6'-(((2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-[1,1'-biphenyl]-3',3-diyl))diacetic acid
AKOS040741338

Research Excerpts

Overview

Bimosiamose is a novel synthetic panselectin antagonist being developed for the treatment of acute and chronic inflammatory disorders.

ExcerptReferenceRelevance
"Bimosiamose is a novel synthetic panselectin antagonist being developed for the treatment of acute and chronic inflammatory disorders. "( Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration.
Jilma, B; Meyer, M; Wolff, G; Zahlten, R, 2005)		2.02
"Bimosiamose is a novel synthetic pan-selectin antagonist developed for the treatment of acute and chronic inflammatory disorders. "( The pharmacokinetics of subcutaneously injected Bimosiamose disodium in healthy male volunteers.
Beyer, D; Jilma, B; Meyer, M; Vollhardt, K; Woischwill, C; Wolff, G, 2007)		2.04

Treatment

ExcerptReferenceRelevance
"Treatment with bimosiamose had no significant effect on LPS-induced TF expression, as quantified by TF mRNA levels, or on LPS-induced coagulation response, reflected by increases in plasma thrombin-antithrombin (TAT) complexes and prothrombin fragment (F1 + 2) levels."( Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia.
Beyer, D; Firbas, C; Jilma, B; Leitner, JM; Mayr, FB; Meyer, M; Reiter, RA; Spiel, AO; Wolff, G, 2008)		0.95

Toxicity

ExcerptReferenceRelevance
" Bimosiamose was safe and well-tolerated."( Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration.
Jilma, B; Meyer, M; Wolff, G; Zahlten, R, 2005)		1.48

Pharmacokinetics

ExcerptReferenceRelevance
" This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties."( Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.
Bedard, PW; Clerin, V; Di, L; Huang, A; Janz, K; Kaila, N; Keith, JC; Lowe, M; Moretto, A; Schaub, RG; Shaw, GD; Sushkova, N; Tam, S; Tchernychev, B; Tsao, DH; Wang, Q, 2010)		0.36

Bioavailability

ExcerptReferenceRelevance
" Systemic bioavailability after inhalation is low."( Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males.
Aydt, E; Beeh, KM; Beier, J; Beyer, D; Jilma, B; Meyer, M; Wolff, G; Zahlten, R, 2007)		0.6
" However, its oral bioavailability was low."( Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.
Bedard, PW; Clerin, V; Di, L; Huang, A; Janz, K; Kaila, N; Keith, JC; Lowe, M; Moretto, A; Schaub, RG; Shaw, GD; Sushkova, N; Tam, S; Tchernychev, B; Tsao, DH; Wang, Q, 2010)		0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency40.53340.007215.758889.3584AID624030
GLI family zinc finger 3Homo sapiens (human)Potency0.00300.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency26.83250.000221.22318,912.5098AID743063
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P-selectinHomo sapiens (human)IC50 (µMol)82.50005.00005.00005.0000AID280291; AID499878
E-selectinHomo sapiens (human)IC50 (µMol)500.00000.02002.21336.6000AID280289
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
cell adhesionL-selectinHomo sapiens (human)
leukocyte cell-cell adhesionL-selectinHomo sapiens (human)
calcium-dependent cell-cell adhesion via plasma membrane cell adhesion moleculesL-selectinHomo sapiens (human)
leukocyte tethering or rollingL-selectinHomo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesL-selectinHomo sapiens (human)
response to cytokineL-selectinHomo sapiens (human)
positive regulation of leukocyte migrationP-selectinHomo sapiens (human)
inflammatory responseP-selectinHomo sapiens (human)
cell adhesionP-selectinHomo sapiens (human)
leukocyte cell-cell adhesionP-selectinHomo sapiens (human)
positive regulation of platelet activationP-selectinHomo sapiens (human)
calcium-dependent cell-cell adhesion via plasma membrane cell adhesion moleculesP-selectinHomo sapiens (human)
response to lipopolysaccharideP-selectinHomo sapiens (human)
regulation of integrin activationP-selectinHomo sapiens (human)
defense response to Gram-negative bacteriumP-selectinHomo sapiens (human)
leukocyte tethering or rollingP-selectinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP-selectinHomo sapiens (human)
cell-cell adhesionP-selectinHomo sapiens (human)
positive regulation of leukocyte tethering or rollingP-selectinHomo sapiens (human)
response to cytokineP-selectinHomo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesP-selectinHomo sapiens (human)
positive regulation of receptor internalizationE-selectinHomo sapiens (human)
leukocyte migration involved in inflammatory responseE-selectinHomo sapiens (human)
positive regulation of leukocyte migrationE-selectinHomo sapiens (human)
inflammatory responseE-selectinHomo sapiens (human)
heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesE-selectinHomo sapiens (human)
leukocyte cell-cell adhesionE-selectinHomo sapiens (human)
activation of phospholipase C activityE-selectinHomo sapiens (human)
calcium-mediated signalingE-selectinHomo sapiens (human)
actin filament-based processE-selectinHomo sapiens (human)
response to lipopolysaccharideE-selectinHomo sapiens (human)
response to tumor necrosis factorE-selectinHomo sapiens (human)
regulation of inflammatory responseE-selectinHomo sapiens (human)
leukocyte tethering or rollingE-selectinHomo sapiens (human)
response to interleukin-1E-selectinHomo sapiens (human)
positive regulation of leukocyte tethering or rollingE-selectinHomo sapiens (human)
response to cytokineE-selectinHomo sapiens (human)
cellular response to interleukin-6P-selectin glycoprotein ligand 1Homo sapiens (human)
cell adhesionP-selectin glycoprotein ligand 1Homo sapiens (human)
symbiont entry into host cellP-selectin glycoprotein ligand 1Homo sapiens (human)
leukocyte migrationP-selectin glycoprotein ligand 1Homo sapiens (human)
leukocyte tethering or rollingP-selectin glycoprotein ligand 1Homo sapiens (human)
leukocyte adhesive activationP-selectin glycoprotein ligand 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
protease bindingL-selectinHomo sapiens (human)
calcium ion bindingL-selectinHomo sapiens (human)
protein bindingL-selectinHomo sapiens (human)
heparin bindingL-selectinHomo sapiens (human)
carbohydrate bindingL-selectinHomo sapiens (human)
glycosphingolipid bindingL-selectinHomo sapiens (human)
oligosaccharide bindingL-selectinHomo sapiens (human)
sialic acid bindingL-selectinHomo sapiens (human)
lipopolysaccharide bindingP-selectinHomo sapiens (human)
integrin bindingP-selectinHomo sapiens (human)
calcium ion bindingP-selectinHomo sapiens (human)
protein bindingP-selectinHomo sapiens (human)
heparin bindingP-selectinHomo sapiens (human)
sialic acid bindingP-selectinHomo sapiens (human)
fucose bindingP-selectinHomo sapiens (human)
glycosphingolipid bindingP-selectinHomo sapiens (human)
calcium-dependent protein bindingP-selectinHomo sapiens (human)
oligosaccharide bindingP-selectinHomo sapiens (human)
transmembrane signaling receptor activityE-selectinHomo sapiens (human)
protein bindingE-selectinHomo sapiens (human)
sialic acid bindingE-selectinHomo sapiens (human)
phospholipase bindingE-selectinHomo sapiens (human)
metal ion bindingE-selectinHomo sapiens (human)
oligosaccharide bindingE-selectinHomo sapiens (human)
virus receptor activityP-selectin glycoprotein ligand 1Homo sapiens (human)
signaling receptor bindingP-selectin glycoprotein ligand 1Homo sapiens (human)
protein bindingP-selectin glycoprotein ligand 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membraneL-selectinHomo sapiens (human)
secretory granule membraneL-selectinHomo sapiens (human)
external side of plasma membraneL-selectinHomo sapiens (human)
extracellular spaceL-selectinHomo sapiens (human)
extracellular spaceP-selectinHomo sapiens (human)
plasma membraneP-selectinHomo sapiens (human)
external side of plasma membraneP-selectinHomo sapiens (human)
platelet dense granule membraneP-selectinHomo sapiens (human)
platelet alpha granule membraneP-selectinHomo sapiens (human)
extracellular spaceP-selectinHomo sapiens (human)
external side of plasma membraneP-selectinHomo sapiens (human)
extracellular spaceE-selectinHomo sapiens (human)
plasma membraneE-selectinHomo sapiens (human)
caveolaE-selectinHomo sapiens (human)
clathrin-coated pitE-selectinHomo sapiens (human)
cortical cytoskeletonE-selectinHomo sapiens (human)
membrane raftE-selectinHomo sapiens (human)
perinuclear region of cytoplasmE-selectinHomo sapiens (human)
external side of plasma membraneE-selectinHomo sapiens (human)
extracellular spaceE-selectinHomo sapiens (human)
uropodP-selectin glycoprotein ligand 1Homo sapiens (human)
plasma membraneP-selectin glycoprotein ligand 1Homo sapiens (human)
membraneP-selectin glycoprotein ligand 1Homo sapiens (human)
plasma membrane raftP-selectin glycoprotein ligand 1Homo sapiens (human)
plasma membraneP-selectin glycoprotein ligand 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID275268Inhibition of P-selectin-mediated adhesion of HL60 cells2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.
AID280293Inhibition of human L-selectin after 2 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID499878Inhibition of P-selectin in human HL-60 cells2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.
AID275270Effect on antigen-induced airway hyperresponsiveness in allergic sheep at 10 mg aerosol2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.
AID280296Inhibition of attachment of HL60 cells to P-selectin at 109 uM after 5 mins2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID280289Inhibition of human E-selectin after 2 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID280291Inhibition of human P-selectin after 2 hrs2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID280295Inhibition of attachment of HL60 cells to E-selectin at 109 uM after 5 mins2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Rational design of novel, potent small molecule pan-selectin antagonists.
AID275269Effect on survival of kidney allograft in ACI rat at 10 mg/kg, iv2007Journal of medicinal chemistry, Jan-11, Volume: 50, Issue:1
Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (40.00)29.6817
2010's9 (36.00)24.3611
2020's6 (24.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.29 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (32.00%)5.53%
Reviews2 (8.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2,3-dihydroxybenzoic acid
2,3-dihydroxybenzoic acid: RN given refers to parent cpd. dihydroxybenzoic acid : Any member of the class of hydroxybenzoic acids carrying two phenolic hydroxy groups on the benzene ring and its derivatives.. 2,3-dihydroxybenzoic acid : A dihydroxybenzoic acid that is benzoic acid substituted by hydroxy groups at positions 2 and 3. It occurs naturally in Phyllanthus acidus and in the aquatic fern Salvinia molesta.		2.0310dihydroxybenzoic acidhuman xenobiotic metabolite;
plant metabolite
protocatechuic acid
protocatechuic acid: RN given refers to parent cpd; structure. 3,4-dihydroxybenzoic acid : A dihydroxybenzoic acid in which the hydroxy groups are located at positions 3 and 4.		2.0310catechols;
dihydroxybenzoic acid		antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite
gallic acid
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.		2.0310trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
pyrogallol
benzenetriol : A triol in which three hydroxy groups are substituted onto a benzene ring.		2.0310benzenetriol;
phenolic donor		plant metabolite
celecoxib
[no description available]		2.0310organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
methacholine chloride
Methacholine Chloride: A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)		3.4111quaternary ammonium salt
2-methylpentane
Hexanes: Six-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives. Various polyneuropathies are caused by hexane poisoning.		10.27148alkane
cinchophen
cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94		2.0310quinolines
shikimic acid
Shikimic Acid: A tri-hydroxy cyclohexene carboxylic acid important in biosynthesis of so many compounds that the shikimate pathway is named after it.. shikimic acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid substituted by hydroxy groups at positions 3, 4 and 5 (the 3R,4S,5R stereoisomer). It is an intermediate metabolite in plants and microorganisms.		2.0310alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid;
hydroxy monocarboxylic acid		Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
oxycinchophen
[no description available]		2.0310quinolines
2,3,4-Trihydroxybenzoic acid
[no description available]		2.0310hydroxybenzoic acid
mannose
mannopyranose : The pyranose form of mannose.		10.27148D-aldohexose;
D-mannose;
mannopyranose		metabolite
ozone
Ozone: The unstable triatomic form of oxygen, O3. It is a powerful oxidant that is produced for various chemical and industrial uses. Its production is also catalyzed in the ATMOSPHERE by ULTRAVIOLET RAY irradiation of oxygen or other ozone precursors such as VOLATILE ORGANIC COMPOUNDS and NITROGEN OXIDES. About 90% of the ozone in the atmosphere exists in the stratosphere (STRATOSPHERIC OZONE).. ozone : An elemental molecule with formula O3. An explosive, pale blue gas (b.p. -112degreeC) that has a characteristic, pungent odour, it is continuously produced in the upper atmosphere by the action of solar ultraviolet radiation on atmospheric oxygen. It is an antimicrobial agent used in the production of bottled water, as well as in the treatment of meat, poultry and other foodstuffs.		9.3711elemental molecule;
gas molecular entity;
reactive oxygen species;
triatomic oxygen		antiseptic drug;
disinfectant;
electrophilic reagent;
greenhouse gas;
mutagen;
oxidising agent;
tracer
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		2.0310methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
baicalein
[no description available]		2.0310trihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
chrysin
chrysin : A dihydroxyflavone in which the two hydroxy groups are located at positions 5 and 7.		2.03107-hydroxyflavonol;
dihydroxyflavone		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		2.0210antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc
Sialyl Lewis X Antigen: A sialylated version of Lewis X antigen expressed on cell surfaces. It is a ligand for SELECTINS.. alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc : A branched amino tetrasaccharide consisting of a sialyl residue, linked (2->3) to a galactosyl residue that in turn is linked (1->4) to a glucosaminyl residue, which is also carrying a fucosyl residue at the 3-position.		4.0520amino tetrasaccharide;
glucosamine oligosaccharide		epitope
psi 697
2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid: inhibitor of P selectin that decreases vein wall injury in a rat stenosis model of venous thrombosis		2.0510
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		5.8122
lewis x antigen
Lewis X Antigen: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, Lewis X antigen is a stage-specific embryonic antigen.		4.0520
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		2.0210
thromboplastin
Thromboplastin: Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation.		3.4311
ConditionIndicatedRelationship StrengthStudiesTrials
Adjuvant Arthritis
[description not available]		02.0310
Rheumatoid Arthritis
[description not available]		02.0310
Anasarca
[description not available]		02.0310
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.0310
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0310
Carotid Arteriopathies, Traumatic
[description not available]		02.0510
Deep Vein Thrombosis
[description not available]		02.0510
Venous Thrombosis
The formation or presence of a blood clot (THROMBUS) within a vein.		02.0510
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.8721
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Airflow Obstruction, Chronic
[description not available]		05.9731
Pulmonary Disease, Chronic Obstructive
A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.		17.9731
Innate Inflammatory Response
[description not available]		06.5132
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		011.5132
Endotoxemia
A condition characterized by the presence of ENDOTOXINS in the blood. On lysis, the outer cell wall of gram-negative bacteria enters the systemic circulation and initiates a pathophysiologic cascade of pro-inflammatory mediators.		08.4311
Cancer of Liver
[description not available]		02.9710
Colorectal Cancer
[description not available]		02.9710
Liver Neoplasms
Tumors or cancer of the LIVER.		02.9710
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.9710
Bleeding
[description not available]		07.0710
Blood Clot
[description not available]		02.0710
Hemorrhage
Bleeding or escape of blood from a vessel.		02.0710
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		02.0710
Asthma, Bronchial
[description not available]		06.5132
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		011.5132
Injury, Ischemia-Reperfusion
[description not available]		02.0210
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		02.0210
Contact Dermatitis
[description not available]		03.4111
Dizzyness
[description not available]		03.4111
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		03.4111
Dizziness
An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.		03.4111
Palmoplantaris Pustulosis
[description not available]		03.4111
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		15.4111
Diseases of Nasopharynx
[description not available]		03.4211